Ilan Ganot - Sep 2, 2023 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role
Director
Signature
/s/ David Tyronne Howton as attorney-in-fact for Ilan Ganot
Stock symbol
SLDB
Transactions as of
Sep 2, 2023
Transactions value $
$0
Form type
4
Date filed
9/6/2023, 04:40 PM
Previous filing
Jun 8, 2023
Next filing
Dec 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLDB Common Stock Options Exercise +1.58K +1.8% 89.3K Sep 2, 2023 Direct F1, F2
holding SLDB Common Stock 19.4K Sep 2, 2023 See Footnote F3
holding SLDB Common Stock 4.32K Sep 2, 2023 Wife F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLDB Restricted Stock Units Options Exercise $0 -1.58K -50% $0.00 1.58K Sep 2, 2023 Common Stock 1.58K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Represents 85,299 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship.
F3 Represents 19,394 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.
F4 Includes 1,879 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2023.
F5 On December 2, 2022 (the "Grant Date"), Mr. Ganot was granted 6,333 restricted stock units, vesting in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of a change in control the restricted stock units shall accelerate in full.